Improved drug response

11.07.10 Tübingen – A single infusion with the immune modulator cyclophosphamide before vaccination with Immatics’ multi-peptide tumour vaccine IMA901 improves response rate in patients with advanced renal cell carcinoma. 83% of the... more

The EMA is also built on fees

11.07.10 London – It’s bad news for the European Medicines Agency. A new Eurobarometer poll (see page 10) shows that many European citizens don’t trust scientists whose work has been sponsored by industry – regardless of whether they did... more

Hope for young patients

10.07.10 Basel – Roche AG has reported promising Phase III results with its anti-IL-6-antibody drug Roctrema (tocilizumab) in children with systemic juvenile idio­pathic arthritis. Following 3 months’ treatment with the immuno­modulator,... more

Going public with results

10.07.10 Brussels – The EMA is seeking input from drug developers on its new guidance system involving the upload of trial results in a publicly accessible area of the password-protected EudraCT database. Stakeholders are invited to... more

EMA changes attitude towards Rhucin

09.07.10 The EU’s Committee for Human Medicinal Products (CHMP) has changed its mind, and is now recommending Pharming NV’s (Leiden) C1 esterase inhibitor Rhucin for the treatment of rapid tissue swelling (edema) in patients with the... more